A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
This study has been withdrawn prior to enrollment.
(Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.)
Information provided by:
First received: May 7, 2003
Last updated: November 2, 2009
Last verified: November 2009
The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting.
Drug: fondaparinux sodium
Procedure: percutaneous coronary intervention (PCI)
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
| Estimated Enrollment:
| Study Start Date:
|Ages Eligible for Study:
||21 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Scheduled for PCI, including PCI for non-ST elevation acute coronary syndromes (ACS), primary PCI for ST elevation myocardial infarction (MI) or elective PCI (with planned overnight stay in hospital). (Patients undergoing diagnostic heart catherization who are suitable candidates for "ad hoc" PCI are also eligible).
- Age < 21 years
- Activated Clotting Time (ACT) > 200 seconds immediately prior to PCI
- Use of low molecular weight heparin (LMWH) in the previous 6 hours before PCI
- Currently receiving an oral anticoagulant (OAC) agent with an INR > 1.8
- Thrombolytic therapy for ST elevation MI in the previous 24 hours before PCI
- Active internal bleeding or history of hemorrhagic diathesis
- Thrombocytopenia (platelet count < 100 x 10-9/L)
- Pregnant women or women of childbearing potential who are not using an effective method of contraception
- Known allergy to unfractionated heparin, fondaparinux, aspirin or clopidogrel
- Absolute contra-indication to anticoagulation
- Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment or prior participation in this study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00060554
No publications provided
||Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 7, 2003
||November 2, 2009
||United States: Food and Drug Administration
Keywords provided by Schering-Plough:
Acute coronary syndromes
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 29, 2014
Coronary Artery Disease
Arterial Occlusive Diseases
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action